What is the Role of Bevacizumab in Stage IV NSCLC? episode artwork

EPISODE · Apr 15, 2016 · 3 MIN

What is the Role of Bevacizumab in Stage IV NSCLC?

from GRACEcast · host cancerGRACE Meetings

Dr. Jack West, Swedish Cancer Institute, discusses the anti-angiogenic agent bevacizumab (Avastin) and the trial evidence of its efficacy for non-squamous NSCLC.

Episode metadata supplied by the publisher feed · Published Apr 15, 2016

Embed this episode

NOW PLAYING

What is the Role of Bevacizumab in Stage IV NSCLC?

0:00 3:46

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of GRACEcast?

This episode is 3 minutes long.

When was this GRACEcast episode published?

This episode was published on April 15, 2016.

Can I download this GRACEcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!